Non-nucleoside reverse transcriptase inhibitors

A compound represented by formula I:

• wherein
• R2 is selected from:
• H, (C1-4)alkyl, halo, haloalkyl, OH, (C1-6)alkoxy, NH(C1-4alkyl) or N(C1-4alkyl)2;
• R4 is H or Me;
• R5 is H or Me;
• R11 is H, (C1-4)alkyl, (C3-4)cycloalkyl and (C1-4)alkyl-(C3-4)cycloalkyl;
• A is a connecting chain of (C1-3)alkylene;
• B is O or S;
• n is 1;
• wherein Ring C is a 6- or 10-membered aryl
• said aryl being optionally substituted with from 1 to 4 substituents selected from:
• halogen and (C1-6)alkyl optionally substituted with OH;
• E is a single bond connecting group selected from:
• wherein R22 is H or (C1-6)alkyl;
• wherein R23 is H or (C1-6)alkyl;
• wherein R24 is H or (C1-6)alkyl;
• wherein R25 is H or (C1-6)alkyl;
• wherein R26 and R27 is each H or (C1-6)alkyl;
• wherein R28 is H or (C1-6)alkyl;
• wherein R29 is H or (C1-6)alkyl;
• and
• and
• Ring D is a 6- or 10-membered aryl or a 5- or 6-membered heterocycle having from 1 to 4 heteroatoms selected from:
• O, N, and S, said aryl and said heterocycle being optionally substituted with from 1 to 5 substituents selected from:
• halogen, NH2, NO2, COOH, OH, COO(C1-6) alkyl, (C1-6)alkoxy, (C2-4)alkenyl-COOH, (C3-7)cycloalkyl-COOH and (C1-6)alkyl optionally substituted with COOH or OH;
• or a salt or a prodrug thereof.